Chapter

ROSETTA Lung-02: Pumitamig

From ASCO 2026: Lung Cancer Treatment Options, New Studies - Cancer Therapy Advisor by Bryant Furlow

Concepts

1. Pumitamig Therapy

   "First-line therapy with the bispecific antibody pumitamig was associated with “encouraging” overall response rates in both squamous cell and nonsquamous NSCLC regardless of PD-L1 expression levels, a

2. Trial Design

   "In this phase 2/3 study (NCT06712316), 23 patients with nonsquamous NSCLC were randomly assigned to receive pumitamig 1400 mg or 2000 mg; both groups also received carboplatin (AUC5) plus pemetrexed

3. Response Rates

   "Confirmed ORR (cORR) was “encouraging” across doses and histologies, Dr Peters said, at 57.1% for nonsquamous NSCLC patients and 68.4% for squamous NSCLC. cORR was similar across PD-L1 levels, includ

4. Safety Signals

   "The different doses were associated with “similar and manageable” safety signals, and only 1 of 9 hemorrhage TEAEs was grade 3 or higher, Dr Peters said.\n\nAny-grade treatment-related adverse events